Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on Apr. 8-9, 2024. Lexaria CEO Chris Bunka will be presenting at the event, with his presentation scheduled to begin at 10:30 a.m. ET on Tuesday, Apr. 9. Bunka will discuss the company’s recent discovery of enhanced performance of glucagon-like-peptide-1 (“GLP-1”) drugs utilizing DehydraTECH. The presentation will also cover the highly anticipated upcoming animal and clinical studies in humans to more thoroughly evaluate the impact of DehydraTECH processing on the world’s leading GLP-1 drugs.
To view the presentation, visit https://ibn.fm/luSk2
To view the full press release, visit https://ibn.fm/o5K5e
About Lexaria Bioscience Corp.
DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is powered by IBN
